Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, ESAs, Opioids), By Region (APAC, North America, Europe, MEA), And Segment Forecasts, 2022 - 2030

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Scope
  • 1.1.2 Regional Scope
  • 1.1.3 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database:
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List Of Secondary Sources
• 1.9 List Of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Outlook

Chapter 3 Cancer Supportive Care Drugs Market Variables, Trends, And Scope

• 3.1 Market Lineage Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Industry Value Chain Analysis
• 3.4 Regulatory Framework
• 3.5 Supply Demand Analysis
• 3.6 Covid Impact Analysis
• 3.7 Market Dynamics
  • 3.7.1 Market Driver Analysis
    • 3.7.1.1 Growing Cancer Prevalence And Increase In Number Of People Receiving Chemotherapy
    • 3.7.1.2 Large Number Of Side Effects Associated With The Cancer Treatment
  • 3.7.2 Market Restraint Analysis
    • 3.7.2.1 Rising Popularity Of Targeted Therapies For The Treatment Of Cancer In Developed Countries
    • 3.7.2.2 Safety Issues Associated With Supportive Care Agents
  • 3.7.3 Industry Opportunity Analysis
    • 3.7.3.1 Development Of Safer Alternatives For Erythropoiesis-Stimulating Agents And Pain Management Products And Launch Of Biosimilars
  • 3.7.4 Industry Challenges
    • 3.7.4.1 Less Developed Cancer Supportive Cancer Market In Low- And Middle-Income Countries (Lmics)
• 3.8 Pestel Analysis
• 3.9 Industry Analysis - Porter's

Chapter 4 Cancer Supportive Care Drugs Market: Segment Analysis, By Therapeutic Class, 2017 - 2030 (USD Million)

• 4.1 Cancer Supportive Care Drugs Market: Therapeutic Class Movement Analysis
• 4.2 G-Csfs (Granulocyte-Colony Stimulating Factors)
  • 4.2.1 G-Csfs (Granulocyte-Colony Stimulating Factors) Market, 2017 - 2030 (USD Million)
• 4.3 Esas (Erythropoiesis Stimulating Agents)
  • 4.3.1 Esas (Erythropoiesis Stimulating Agents) Market, 2017 - 2030 (USD Million)
• 4.4 Antiemetics
  • 4.4.1 Antiemetics Market, 2017 - 2030 (USD Million)
• 4.5 Bisphosphonates
  • 4.5.1 Bisphosphonates Market, 2017 - 2030 (USD Million)
• 4.6 Opioids
  • 4.6.1 Opioids Market, 2017 - 2030 (USD Million)
• 4.7 Nsaids And Others
  • 4.7.1 Nsaids And Others Market, 2017 - 2030 (USD Million)

Chapter 5 Cancer Supportive Care Drugs Market: Segment Analysis, By Region, 2017 - 2030 (USD Million)

• 5.1 Regional Market Share Analysis, 2021 & 2030
• 5.2 Regional Market Snapshot
• 5.3 Market Size, & Forecasts, Revenue And Trend Analysis, 2021 To 2030
  • 5.3.1 North America
    • 5.3.1.1 North America Market Estimates And Forecast, 2017 - 2030 (USD Million)
    • 5.3.1.2 U.S.
    • 5.3.1.2.1 U.S. Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.1.3 Canada
    • 5.3.1.3.1 Canada Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.1.4 Mexico
    • 5.3.1.4.1 Mexico Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
  • 5.3.2 Europe
    • 5.3.2.1 Europe Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.2.2 U.K.
    • 5.3.2.2.1 U.K. Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.2.3 Germany
    • 5.3.2.3.1 Germany Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.2.4 Spain
    • 5.3.2.4.1 Spain Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.2.5 France
    • 5.3.2.5.1 France Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.2.6 Italy
    • 5.3.2.6.1 Italy Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.2.7 Russia
    • 5.3.2.7.1 Russia Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
  • 5.3.3 Asia Pacific
    • 5.3.3.1 Asia Pacific Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.3.2 Japan
    • 5.3.3.2.1 Japan Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.3.3 China
    • 5.3.3.3.1 China Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.3.4 India
    • 5.3.3.4.1 India Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.3.5 Australia
    • 5.3.3.5.1 Australia Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
  • 5.3.4 Latin America
    • 5.3.4.1 Latin America Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.4.2 Brazil
    • 5.3.4.2.1 Brazil Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
  • 5.3.5 Mea
    • 5.3.5.1 Mea Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    • 5.3.5.2 South Africa
    • 5.3.5.2.1 South Africa Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)

Chapter 6 Cancer Supportive Care Drugs Market: Competitive Analysis

• 6.1 Recent Developments And Impact Analysis, By Key Market Participants
  • 6.1.1 Synergy Analysis: Major Deals And Strategic Alliances
    • 6.1.1.1 New Product Launches
    • 6.1.1.2 Mergers And Acquisitions
    • 6.1.1.3 Licensing Agreements
• 6.2 Company Categorization
  • 6.2.1 Innovators
  • 6.2.2 Market Leaders
  • 6.2.3 Emerging Players
  • 6.2.4 Heat Map Analysis
• 6.3 Vendor Landscape
  • 6.3.1 List Of Potential End-Users
  • 6.3.2 Key Company Market Share Analysis, 2021
  • 6.3.3 Consumer Behaviour Analysis
  • 6.3.4 Competitive Dashboard Analysis
• 6.4 Private Companies
  • 6.4.1 List Of Key Emerging Companies
• 6.5 Company Market Position Analysis
• 6.6 Company Profiles
  • 6.6.1 AMGEN INC.
    • 6.6.1.1 Company overview
    • 6.6.1.2 Financial Performance
    • 6.6.1.3 product benchmarking
    • 6.6.1.4 recent developments
  • 6.6.2 MERCK & CO.
    • 6.6.2.1 Company Overview
    • 6.6.2.2 Financial Performance
    • 6.6.2.3 Product benchmarking
    • 6.6.2.4 Recent developments
  • 6.6.3 JOHNSON & JOHNSON SERVICES, INC.
    • 6.6.3.1 Company Overview
    • 6.6.3.2 Financial Performance
    • 6.6.3.3 Product benchmarking
    • 6.6.3.4 Recent developments
  • 6.6.4 HERON THERAPEUTICS, INC.
    • 6.6.4.1 Company Overview
    • 6.6.4.2 Financial Performance
    • 6.6.4.3 Product benchmarking
    • 6.6.4.4 Recent developments
  • 6.6.5 NOVARTIS AG
    • 6.6.5.1 Company Overview
    • 6.6.5.2 Sandoz International GmbH
    • 6.6.5.3 Financial Performance
    • 6.6.5.4 Product benchmarking
    • 6.6.5.5 Recent developments
  • 6.6.6 GLAXOSMITHKLINE PLC. (TESARO, INC.)
    • 6.6.6.1 Company Overview
    • 6.6.6.2 Financial Performance
    • 6.6.6.3 Product benchmarking
    • 6.6.6.4 Recent developments
  • 6.6.7 F. HOFFMANN-LA ROCHE AG
    • 6.6.7.1 Company Overview
    • 6.6.7.2 Financial Performance
    • 6.6.7.3 Product benchmarking
    • 6.6.7.4 Recent developments
  • 6.6.8 HELSINN HEALTHCARE SA
    • 6.6.8.1 Company Overview
    • 6.6.8.2 Product benchmarking
    • 6.6.8.3 Recent developments

List of Tables

• TABLE 1 List of secondary sources
• TABLE 2 List of Abbreviation
• TABLE 3 Regulatory framework
• TABLE 4 Factors influencing the demand and supply
• TABLE 5 Most prevalent cancers using chemotherapy and/or radiation therapy as a treatment option (2021)
• TABLE 6 Major products: G-CSF
• TABLE 7 Major products: ESAs
• TABLE 8 Major products: Antiemetics
• TABLE 9 Major products: Bisphosphonates
• TABLE 10 Major products: Opioids and non-opioids
• TABLE 11 North America Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 12 U.S. Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 13 Canada Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 14 Mexico Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 15 Europe Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 16 U.K. Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 17 Germany Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 18 Italy Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 19 France Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 20 Spain Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 21 Russia Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 22 Asia Pacific Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 23 Japan Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 24 China Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 25 India Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 26 Australia Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 27 Latin America Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 28 Brazil Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 29 MEA Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
• TABLE 30 South Africa Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)

List of Figures

• FIG. 1 Cancer supportive care drugs market segmentation
• FIG. 2 Market research process
• FIG. 3 Information procurement
• FIG. 4 Primary research pattern
• FIG. 5 Market research approaches
• FIG. 6 Value-chain-based sizing & forecasting
• FIG. 7 QFD modeling for market share assessment
• FIG. 8 Market formulation & validation
• FIG. 9 Commodity Flow Approach
• FIG. 10 Market outlook (2021)
• FIG. 11 Penetration and growth prospect mapping
• FIG. 12 Penetration and growth prospect mapping
• FIG. 13 Cancer supportive care drugs market driver impact
• FIG. 14 Global population by age group, 2016, 2021, & 2027
• FIG. 15 Cancer supportive care drugs market restraint impact
• FIG. 16 PESTEL analysis
• FIG. 17 Porter's five forces analysis
• FIG. 18 Cancer Supportive Care Drugs therapeutic class outlook: Key takeaways
• FIG. 19 Cancer supportive care drugs market: Therapeutic class movement analysis (USD Million)
• FIG. 20 G-CSFs (Granulocyte-colony Stimulating Factors), 2017 - 2028 (USD Million)
• FIG. 21 ESAs (Erythropoiesis Stimulating Agents) market, 2017 - 2028 (USD Million)
• FIG. 22 Antiemetics market, 2017 - 2028 (USD Million)
• FIG. 23 Bisphosphonates market, 2017 - 2028 (USD Million)
• FIG. 24 Opioids market, 2017 - 2028 (USD Million)
• FIG. 25 NSAIDs and others market, 2017 - 2028 (USD Million)
• FIG. 26 Regional outlook, 2021 &2030
• FIG. 27 Regional marketplace: Key takeaways
• FIG. 28 North America
• FIG. 29 North America Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 30 U.S.
• FIG. 31 U.S. Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 32 Canada
• FIG. 33 Canada Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 34 Mexico
• FIG. 35 Mexico Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 36 Europe
• FIG. 37 Europe Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 38 U.K.
• FIG. 39 U.K. Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 40 Germany
• FIG. 41 Germany Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 42 Spain
• FIG. 43 Spain Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 44 France
• FIG. 45 France Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 46 Italy
• FIG. 47 Italy Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 48 Russia
• FIG. 49 Russia Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 50 Asia Pacific
• FIG. 51 Asia Pacific Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 52 Japan
• FIG. 53 Japan Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 54 China
• FIG. 55 China Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 56 India
• FIG. 57 India Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 58 Australia
• FIG. 59 Australia Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 60 Latin America
• FIG. 61 Latin America Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 62 Brazil
• FIG. 63 Brazil Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 64 Middle East and Africa
• FIG. 65 MEA Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million).
• FIG. 66 South Africa
• FIG. 67 South Africa Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
• FIG. 68 Heat map analysis
• FIG. 69 Company market position analysis (2021)
• FIG. 70 Consumer behavior analysis
• FIG. 71 Market differentiators
• FIG. 72 Company market position analysis, 2021
• FIG. 73 Company market position analysis, 2021